Tags

Type your tag names separated by a space and hit enter

Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
J Alzheimers Dis 2017; 58(3):909-918JA

Abstract

BACKGROUND

Episodic memory impairment is the core feature of typical Alzheimer's disease.

OBJECTIVE

To evaluate the performance of two commonly used verbal memory tests to detect mild cognitive impairment due to Alzheimer's disease (MCI-AD) and to predict progression to Alzheimer's disease dementia (AD-d).

METHODS

Prospective study of MCI patients in a tertiary memory disorder unit. Patients underwent an extensive neuropsychological battery including two tests of declarative verbal memory: The Free and Cued Selective Reminding Test (FCSRT) and the word list learning task from the Consortium to Establish a Registry for Alzheimer's disease (CERAD-WL). Cerebrospinal fluid (CSF) was obtained from all patients and MCI-AD was defined by means of the t-Tau/Aβ1-42 ratio. Logistic regression analyses tested whether the combination of FCSRT and CERAD-WL measures significantly improved the prediction of MCI-AD. Progression to AD-d was analyzed in a Cox regression model.

RESULTS

A total of 202 MCI patients with a mean follow-up of 34.2±24.2 months were included and 98 (48.5%) met the criteria for MCI-AD. The combination of FCSRT and CERAD-WL measures improved MCI-AD classification accuracy based on CSF biomarkers. Both tests yielded similar global predictive values (59.9-65.3% and 59.4-62.8% for FCSRT and CERAD-WL, respectively). MCI-AD patients with deficits in both FCSRT and CERAD-WL had a faster progression to AD-d than patients with deficits in only one test.

CONCLUSIONS

The combination of FCSRT and CERAD-WL improves the classification of MCI-AD and defines different prognostic profiles. These findings have important implications for clinical practice and the design of clinical trials.

Authors+Show Affiliations

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Barcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain.

Pub Type(s)

Evaluation Studies
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28527215

Citation

Sala, Isabel, et al. "Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment Due to Alzheimer's Disease." Journal of Alzheimer's Disease : JAD, vol. 58, no. 3, 2017, pp. 909-918.
Sala I, Illán-Gala I, Alcolea D, et al. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. J Alzheimers Dis. 2017;58(3):909-918.
Sala, I., Illán-Gala, I., Alcolea, D., Sánchez-Saudinós, M. B., Salgado, S. A., Morenas-Rodríguez, E., ... Lleó, A. (2017). Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Alzheimer's Disease : JAD, 58(3), pp. 909-918. doi:10.3233/JAD-170073.
Sala I, et al. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment Due to Alzheimer's Disease. J Alzheimers Dis. 2017;58(3):909-918. PubMed PMID: 28527215.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. AU - Sala,Isabel, AU - Illán-Gala,Ignacio, AU - Alcolea,Daniel, AU - Sánchez-Saudinós,Ma Belén, AU - Salgado,Sergio Andrés, AU - Morenas-Rodríguez,Estrella, AU - Subirana,Andrea, AU - Videla,Laura, AU - Clarimón,Jordi, AU - Carmona-Iragui,María, AU - Ribosa-Nogué,Roser, AU - Blesa,Rafael, AU - Fortea,Juan, AU - Lleó,Alberto, PY - 2017/5/21/pubmed PY - 2018/3/22/medline PY - 2017/5/21/entrez KW - Alzheimer’s disease KW - biomarkers KW - cerebrospinal fluid KW - episodic memory KW - mild cognitive impairment KW - mild neurocognitive disorder KW - neuropsychological test SP - 909 EP - 918 JF - Journal of Alzheimer's disease : JAD JO - J. Alzheimers Dis. VL - 58 IS - 3 N2 - BACKGROUND: Episodic memory impairment is the core feature of typical Alzheimer's disease. OBJECTIVE: To evaluate the performance of two commonly used verbal memory tests to detect mild cognitive impairment due to Alzheimer's disease (MCI-AD) and to predict progression to Alzheimer's disease dementia (AD-d). METHODS: Prospective study of MCI patients in a tertiary memory disorder unit. Patients underwent an extensive neuropsychological battery including two tests of declarative verbal memory: The Free and Cued Selective Reminding Test (FCSRT) and the word list learning task from the Consortium to Establish a Registry for Alzheimer's disease (CERAD-WL). Cerebrospinal fluid (CSF) was obtained from all patients and MCI-AD was defined by means of the t-Tau/Aβ1-42 ratio. Logistic regression analyses tested whether the combination of FCSRT and CERAD-WL measures significantly improved the prediction of MCI-AD. Progression to AD-d was analyzed in a Cox regression model. RESULTS: A total of 202 MCI patients with a mean follow-up of 34.2±24.2 months were included and 98 (48.5%) met the criteria for MCI-AD. The combination of FCSRT and CERAD-WL measures improved MCI-AD classification accuracy based on CSF biomarkers. Both tests yielded similar global predictive values (59.9-65.3% and 59.4-62.8% for FCSRT and CERAD-WL, respectively). MCI-AD patients with deficits in both FCSRT and CERAD-WL had a faster progression to AD-d than patients with deficits in only one test. CONCLUSIONS: The combination of FCSRT and CERAD-WL improves the classification of MCI-AD and defines different prognostic profiles. These findings have important implications for clinical practice and the design of clinical trials. SN - 1875-8908 UR - https://www.unboundmedicine.com/medline/citation/28527215/Diagnostic_and_Prognostic_Value_of_the_Combination_of_Two_Measures_of_Verbal_Memory_in_Mild_Cognitive_Impairment_due_to_Alzheimer's_Disease_ L2 - https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-170073 DB - PRIME DP - Unbound Medicine ER -